Ventus Therapeutics, a clinical-stage biopharmaceutical company with two novel small-molecule programs entering Phase 2 development for immunology, inflammation, and neurology disorders, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback